Breaking News

Aproximaciones multiómicas aplicadas al lavado broncoalveolar para identificar biomarcadores predictivos de respuesta terapéutica en el asma grave FEV1 Decline and Clinical Predictors in Asthma after 10 Years of Follow-Up: BMI as a Modifiable Risk Factor El Papel de la Biopsia Bronquial en la Predicción de la Respuesta a la Terapia Biológica en el Asma Grave No Controlada: Un Estudio Prospectivo Leptin augments IL-13–induced airway eotaxins and submucosal eosinophilia in obesity-associated asthma A proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODY molecule

benralizumab

Subscribe to this category

027

Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype

Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype

18 diciembre, 2024 Like 0 Revisiones Asma

Artículo selecciondo: David J. Jackson, Ph.D., Michael E. Wechsler, M.D., Danie..

Leer más

027

Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme

Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme

18 diciembre, 2024 Like 0 Revisiones Asma

Articulo seleccionado: Jackson D, Pelaia G, Emmanuel B, et al. Benralizumab in s..

Leer más

027

Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial.

Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial.

18 diciembre, 2024 Like 0 Revisiones Asma

Artículo seleccionado: Sanjay Ramakrishnan, Richard E K Russell, Hafiz R Mahmoo..

Leer más

Categorías